Thursday, May 29, 2014

Trimel Pharmaceuticals Corporation - TRL.t

Trimel Pharmaceuticals Corporation - TRL.t is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.

The Corporation holds a licence for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system (“TriVair™”).






On May 28, 2014 the company reported NEWS

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto™ (testosterone), formerly CompleoTRT™, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto™ is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children.

“In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages,” said Dr. Jeffrey Rosen, the medical director and founder of Clinical Research of South Florida (CRSA). “For these patients seeking to restore their testosterone levels, Natesto™ will offer an alternative delivery system that is safer and more convenient than the other options currently available on the market.”
___________________________________________________________





http://pennystockjournal.blogspot.com/2014/05/trimel-pharmaceuticals-corporation-trlt.html